Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 11 to 14 amino acid residues in defined sequence
Reexamination Certificate
2005-04-12
2005-04-12
Russel, Jeffrey Edwin (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
11 to 14 amino acid residues in defined sequence
C514S002600, C514S008100, C514S013800, C514S014800, C514S015800, C514S016700, C514S04400A, C530S322000, C530S328000, C530S345000, C536S023100
Reexamination Certificate
active
06878805
ABSTRACT:
The present invention relates to novel amphipathic peptide-conjugated oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating the compounds to amphipathic moieties such as amphipathic peptides.
REFERENCES:
patent: 4587044 (1986-05-01), Miller et al.
patent: 4605735 (1986-08-01), Miyoshi et al.
patent: 4667025 (1987-05-01), Miyoshi et al.
patent: 4762779 (1988-08-01), Snitman
patent: 4789737 (1988-12-01), Miyoshi et al.
patent: 4824941 (1989-04-01), Gordon et al.
patent: 4828979 (1989-05-01), Klevan et al.
patent: 4835263 (1989-05-01), Nguyen et al.
patent: 4876335 (1989-10-01), Yamane et al.
patent: 4904582 (1990-02-01), Tullis
patent: 4948882 (1990-08-01), Ruth
patent: 4958013 (1990-09-01), Letsinger
patent: 5082830 (1992-01-01), Brakel et al.
patent: 5109124 (1992-04-01), Ramachandran et al.
patent: 5112963 (1992-05-01), Pieles et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5138045 (1992-08-01), Cook et al.
patent: 5214136 (1993-05-01), Lin et al.
patent: 5218105 (1993-06-01), Cook et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5254469 (1993-10-01), Warren, III et al.
patent: 5258506 (1993-11-01), Urdea
patent: 5262536 (1993-11-01), Hobbs, Jr.
patent: 5272250 (1993-12-01), Spielvogel et al.
patent: 5292873 (1994-03-01), Rokita et al.
patent: 5317098 (1994-05-01), Shizuya et al.
patent: 5371241 (1994-12-01), Brush et al.
patent: 5391723 (1995-02-01), Priest
patent: 5414077 (1995-05-01), Lin et al.
patent: 5416203 (1995-05-01), Letsinger
patent: 5451463 (1995-09-01), Nelson et al.
patent: 5486603 (1996-01-01), Buhr
patent: 5510475 (1996-04-01), Agrawal et al.
patent: 5512439 (1996-04-01), Hornes et al.
patent: 5512667 (1996-04-01), Reed et al.
patent: 5514785 (1996-05-01), Van Ness et al.
patent: 5525465 (1996-06-01), Haralambidis et al.
patent: 5541313 (1996-07-01), Ruth
patent: 5545730 (1996-08-01), Urdea et al.
patent: 5552538 (1996-09-01), Urdea et al.
patent: 5565552 (1996-10-01), Magda et al.
patent: 5567810 (1996-10-01), Weis et al.
patent: 5574142 (1996-11-01), Meyer, Jr. et al.
patent: 5578717 (1996-11-01), Urdea et al.
patent: 5578718 (1996-11-01), Cook et al.
patent: 5580731 (1996-12-01), Chang et al.
patent: 5585481 (1996-12-01), Arnold, Jr. et al.
patent: 5587371 (1996-12-01), Sessler et al.
patent: 5591584 (1997-01-01), Chang et al.
patent: 5595726 (1997-01-01), Magda et al.
patent: 5597696 (1997-01-01), Linn et al.
patent: 5599923 (1997-02-01), Sessler et al.
patent: 5599928 (1997-02-01), Hemmi et al.
patent: 5608046 (1997-03-01), Cook et al.
patent: 5688941 (1997-11-01), Cook et al.
patent: 6379884 (2002-04-01), Wada et al.
patent: 6559279 (2003-05-01), Manoharan et al.
patent: 20030003584 (2003-01-01), Adams
patent: 20030148928 (2003-08-01), Beigelman et al.
patent: 20040006203 (2004-01-01), Maier et al.
patent: 11-290073 (1999-10-01), None
patent: WO 9307883 (1993-04-01), None
patent: WO 0072869 (2000-12-01), None
Drin et al. Translocation of the pAntp Peptide. . . biochemistry. vol. 40, No. 6, pp. 1824-1834 (2001).*
Villa et al. Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid . . . FEBS Letters. vol. 473, pp. 241-248 (2000).*
Copy of the PCT International Search Report dated Feb. 6, 2004 (PCT/US03/25567).
Auvray, P., et al., “PAAn-1b and PAAn-E: Two phosphorothioate antisense oligodeoxynucleotides inhibit human aromatase gene expression,”Biochem. Biophys. Res. Commun., 1998, 253, 1-9.
Bandyopadhyay, P., et al., “Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides,”J. Biol. Chem., Apr. 9, 1999, 274(15), 10163-10172.
Crooke, S.T., et al., “Pharmacokinetic properties of several novel oligonucleotide analogs in mice,”J. Pharmacol. Exp. Ther., 1996, 277(2), 923-937.
Demeneix, B.A., et al., “Delivery of polynucleotides with polyamine lipids and polymers,”Nucleosides Nucleotides, 1997, 16(7-9), 1121-1127.
Derossi, D., et al., “The third helix of the antennapedia homeodomain translocates through biological membranes,”The Journal of Biological Chemistry, 1994, 269(14), 10444-10450.
Derossi, D., et al., “Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent,”The Journal of Biological Chemistry, 1996, 271(30), 18188-18193.
Dheur, S., et al., “Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides,”Antisense Nucleic Acid Drug Dev., 1999, 9, 515-525.
Dheur, S., et al., “Polyethyleneimine-mediated transfection to improve antisense activity of 3′-capped phosphodiester oligonucleotides,”Methods Enzymol., 1999, 313, 56-73.
Good, L., et al., “Bactericidal antisense effects of peptide-PNA conjugates,”Nature Biotechnology, Apr. 2001, 19, 360-364.
Kabanov, A.V., “A new class of antivirals: antisense olgonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells,”FEBS Letts., 1990, 259, 327-330.
Kren, B.T., et al., Correction of the UDP-glucuronosyltransferase gene defect in the gunn rat model of crigler-najjar syndrome type 1 with a chimeric oligonucleotide,Proc. Natl. Acad. Sci. U.S.A., Aug. 1999, 96, 10349-10354.
Letsinger, R. L. et al., “Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture,”Proc. Natl. Acad. Sci., 1989, 86, 6553-6556.
Manoharan, M. et al., “Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications,”Biorg. Med. Chem. Letts., 1993, 3(12), 2765-2770.
Manoharan M. et al., “Cholic Acid-Oligonucliotide Conjugates for Antisense Applications,”Bioorganic Med. Chem. Letts., 1994, 4, 1053-1060.
Manoharan, M. et al., “Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides,”Annals NY Acad. Sciences, 1992, 660, 306-309.
Manoharan, M. et al., “Lipidic Nucleic Acids.”Tetrahedron Letts., 1995, 36, 3651-3654.
Manoharan, M. et al., “Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents,”Nucleosides and Nucleotides, 1995, 14, 969-973.
Mishra, R. K. et al., “Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-medicated delivery,”Biochim. Et Biophysica, 1995, 1264, 229-237.
Mitchell, D., et al., “Polyarginine enters cells more efficiently than other polycationic homopolymers,”J. Pepetides Res., 2000, 56, 318-325.
Oberhauser, B. et al., “Effective incorporation of 2′O-methyl-oligonucleotides into liposomes and enhanced cell association through modification with thiocholesterol,”Nucl. Acids Res., 1992, 20, 533-538.
Oehlke, J., et al., “Cellular uptake of an α-helical amphipathis model peptide with the potential to deliver polar compounds into the cell interior non-endocytically,,”J. Biochimica et Biophysica Acta, 1998, 1414, 127-139.
Pillot, T., et al., “Fusogenic properties of the C-terminal domain of the alzheimer β-amyloid peptide,”J. Biol Chem., Nov. 15, 1996, 271(46), 28757-28765.
Pooga, M., et al., “Cellular translocation of proteins by transportan,”The FASEB J., 2001, Express Article 10.1096/fj.00-078fje, published online date Apr. 18, 2001, 13 pages.
Pooga, M., “Cell penetration by transportan,”The FASEB J., 1998, 12, 67-77.
Saison-Behmoaras, T. et al., “Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.”EMBO J., 1991, 10, 1111-1118.
Schwarze, S., “In vivo protein transduction: delivery of a biologically active protein into the mouse,
Maier Martin A.
Manoharan Muthiah
ISIS Pharmaceuticals Inc.
Russel Jeffrey Edwin
Woodcock & Washburn LLP
LandOfFree
Peptide-conjugated oligomeric compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide-conjugated oligomeric compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide-conjugated oligomeric compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3392936